KLHL30

Across TCGA pan-cancer cohorts, KLHL30 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of KLHL30’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where KLHL30 RNA is repressed in tumor relative to normal tissue. In most cancer types KLHL30 is over-expressed in tumor, although a few such as BLCA and KIRC show the opposite, repressed pattern.

BLCA, KIRC, and BRCA are the cancer types where KLHL30 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KLHL30 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−2.084	<.001	8	view →
KIRC	Male	II,III,IV	−0.691	<.001	8	view →
BRCA	All	III,IV	−1.334	<.001	6	view →
KICH	Female	II,III,IV	−1.087	<.001	6	view →
LUSC	Female	II,III,IV	−0.938	<.001	6	view →
THCA	Female	All	+0.708	<.001	5	view →
LIHC	All	All	+0.264	<.001	5	view →
UCEC	All	III,IV	−0.994	.009	4	view →
PRAD	All	All	−0.614	<.001	2	view →
READ	All	All	−0.525	.017	2	view →
CHOL	All	All	+0.950	.011	1	view →
COAD	Female	IV	+0.755	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

KLHL30–BLCA

Open the BLCA breakdown →